CN116848095B - 氘代化合物 - Google Patents

氘代化合物 Download PDF

Info

Publication number
CN116848095B
CN116848095B CN202280014488.6A CN202280014488A CN116848095B CN 116848095 B CN116848095 B CN 116848095B CN 202280014488 A CN202280014488 A CN 202280014488A CN 116848095 B CN116848095 B CN 116848095B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
compound according
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202280014488.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN116848095A (zh
Inventor
舒楚天
田劲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Libon Pharmaceutical Jiangsu Co ltd
Original Assignee
Libang Biopharmaceutical Jiangsu Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Libang Biopharmaceutical Jiangsu Co ltd filed Critical Libang Biopharmaceutical Jiangsu Co ltd
Publication of CN116848095A publication Critical patent/CN116848095A/zh
Application granted granted Critical
Publication of CN116848095B publication Critical patent/CN116848095B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN202280014488.6A 2021-08-13 2022-08-09 氘代化合物 Active CN116848095B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/112521 2021-08-13
CN2021112521 2021-08-13
CN2022106648 2022-07-20
CNPCT/CN2022/106648 2022-07-20
PCT/CN2022/111089 WO2023016440A1 (en) 2021-08-13 2022-08-09 Deuterated compounds

Publications (2)

Publication Number Publication Date
CN116848095A CN116848095A (zh) 2023-10-03
CN116848095B true CN116848095B (zh) 2024-05-24

Family

ID=85199822

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280014488.6A Active CN116848095B (zh) 2021-08-13 2022-08-09 氘代化合物

Country Status (11)

Country Link
US (1) US20240270731A1 (https=)
EP (1) EP4384507A4 (https=)
JP (1) JP2024532807A (https=)
KR (1) KR20240047401A (https=)
CN (1) CN116848095B (https=)
AR (1) AR126778A1 (https=)
CA (1) CA3227149A1 (https=)
IL (1) IL310176A (https=)
MX (1) MX2024001889A (https=)
TW (1) TW202320762A (https=)
WO (1) WO2023016440A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118480034B (zh) * 2023-02-13 2025-02-11 礼邦医药(香港)有限公司 氘代化合物的晶型或盐
TW202547458A (zh) * 2024-03-26 2025-12-16 香港商禮邦醫藥（香港）有限公司 用於治療體染色體顯性多囊性腎病之方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1509173A (zh) * 2001-05-15 2004-06-30 - 用作糖尿病治疗中的PPAR－α和PPAR－γ激活剂的羧酸取代的噁唑衍生物
CN109265380A (zh) * 2017-10-18 2019-01-25 深圳市塔吉瑞生物医药有限公司 取代的丙-2-烯-1-酮化合物及其药物组合物
CN110300580A (zh) * 2017-02-21 2019-10-01 基恩菲特公司 Ppar激动剂与fxr激动剂的组合
CN112209896A (zh) * 2019-07-10 2021-01-12 苏州泽璟生物制药股份有限公司 噻唑烷二酮衍生物以及包含其的药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
WO2020156683A1 (en) * 2019-02-01 2020-08-06 F. Hoffmann-La Roche Ag Aleglitazar for use in the treatment or prevention of major adverse cardiac events
CN118480034B (zh) * 2023-02-13 2025-02-11 礼邦医药(香港)有限公司 氘代化合物的晶型或盐

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1509173A (zh) * 2001-05-15 2004-06-30 - 用作糖尿病治疗中的PPAR－α和PPAR－γ激活剂的羧酸取代的噁唑衍生物
CN110300580A (zh) * 2017-02-21 2019-10-01 基恩菲特公司 Ppar激动剂与fxr激动剂的组合
CN109265380A (zh) * 2017-10-18 2019-01-25 深圳市塔吉瑞生物医药有限公司 取代的丙-2-烯-1-酮化合物及其药物组合物
CN112209896A (zh) * 2019-07-10 2021-01-12 苏州泽璟生物制药股份有限公司 噻唑烷二酮衍生物以及包含其的药物组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design;Nicholas A. Meanwell;J. Med. Chem.;第54卷;2529-2591 *

Also Published As

Publication number Publication date
TW202320762A (zh) 2023-06-01
CA3227149A1 (en) 2023-02-16
AR126778A1 (es) 2023-11-15
US20240270731A1 (en) 2024-08-15
EP4384507A4 (en) 2025-06-18
CN116848095A (zh) 2023-10-03
EP4384507A1 (en) 2024-06-19
JP2024532807A (ja) 2024-09-10
WO2023016440A1 (en) 2023-02-16
AU2022327461A1 (en) 2024-02-01
KR20240047401A (ko) 2024-04-12
MX2024001889A (es) 2024-02-29
IL310176A (en) 2024-03-01

Similar Documents

Publication Publication Date Title
CN111138301B (zh) 联苯类化合物、其中间体、制备方法、药物组合物及应用
JP2025131575A (ja) Ｍａｓ関連ｇタンパク質受容体ｘ４のモジュレーターおよび関連製品ならびに方法
AU781141B2 (en) Novel use of phenylheteroalkylamine derivatives
RU2515968C2 (ru) 5-членное гетероциклическое соединение и его применение для лекарственных целей
CN116848095B (zh) 氘代化合物
WO2004092117A1 (en) Para-sulfonyl substituted phenyl compounds as modulators of ppars
JP2010528061A (ja) ７員環化合物及びその糖尿病と代謝症候群を治療するための薬学的用途
TW202135831A (zh) 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途
KR100622461B1 (ko) 2환식 화합물
US8349862B2 (en) Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia
CN118480034B (zh) 氘代化合物的晶型或盐
AU2022327461B2 (en) Deuterated compounds
JPS6160656A (ja) ロイコトリエン拮抗剤
ES2691548T3 (es) Sales de moduladores de PPAR y métodos para tratar desórdenes metabólicos
HK40092869A (zh) 氘代化合物
HK40092869B (zh) 氘代化合物
JP2011506485A (ja) 糖尿病治療用のオクタヒドロキノリジン
RU2815715C2 (ru) Модуляторы связанных с mas рецепторов g-белка x4 и связанные с ними продукты и способы
HK40052029A (en) Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
KR20010097480A (ko) 새로운 구조를 갖는 ｃｄｋ 저해제

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40092869

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240428

Address after: Building 8, Chuangfu Workshop, No.1 Chuangfu Road, Hanjiang District, Yangzhou City, Jiangsu Province

Applicant after: Libang Biopharmaceutical (Jiangsu) Co.,Ltd.

Country or region after: China

Address before: 1st Floor, 50 Tai Wan New Village, Rong Shu Wan, Lamma Island, Hong Kong, China

Applicant before: Li Bang Pharmaceutical (Hong Kong) Co.,Ltd.

Country or region before: Hong-Kong

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Building 8, Chuangfu Workshop, No.1 Chuangfu Road, Hanjiang District, Yangzhou City, Jiangsu Province, 225129

Patentee after: Libon Pharmaceutical (Jiangsu) Co.,Ltd.

Country or region after: China

Address before: Building 8, Chuangfu Workshop, No.1 Chuangfu Road, Hanjiang District, Yangzhou City, Jiangsu Province, 225129

Patentee before: Libang Biopharmaceutical (Jiangsu) Co.,Ltd.

Country or region before: China